Daniel Sumarriva, Senior Director of Molecular Science Liaisons at Caris Life Sciences, shared a post on LinkedIn about a paper he co-authored with colleagues published in Expert Review of Anticancer Therapy:

“After profiling over 45,000 NSCLC tumors, the documentation of EGFR resistant data, including the prevalence of resistance mutations (718, 721, 797, etc.) in lung cancer, is essential to raise awareness about the significance of repeating molecular profiling post-TKI failure to gain a more precise understanding of resistance mechanisms.

Grateful for the opportunity to work on this publication with Dr. Luis E Raez – Memorial Cancer Institute. A team effort with our Caris Life Sciences Precision Oncology Alliance (POA). Congrats to all the authors: Yasmine Baca, Jennifer Ribeiro, Stephen Liu, Jorge Nieva, Hirva Mamdani, Gilberto de lima Lopes, Hossein Borghaei, Hina Khan, Misako Nagasaka, Antoinette Wozniak and institutions.”

“Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)”

Authors: Luis Raez, Yasmine Baca, Jennifer Ribeiro, Jorge Nieva, Hirva Mamdani, Gilberto Lopes, Hossein Borghaei, Mark Socinski, Antoinette Wozniak, Ari Vanderwalde, Carlos Carracedo Uribe, Daniel Sumarriva, Hina Khan, Stephen Liu and Misako Nagasaka.

Daniel Sumarriva: Prevalence and molecular correlates of acquired EGFR resistance mutations in NSCLC

More posts featuring Daniel Sumarriva.